Netherton Syndrome Clinical Trial
Official title:
EvasayilTM : A Placebo-controlled Trial to Evaluate the Efficacy and Safety of Spesolimab in the Treatment of Patients With Netherton Syndrome
This study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years and older. The purpose of this study is to find out whether a medicine called spesolimab helps people with NS. Participants are divided into a spesolimab and a placebo group. Placebo injections look like spesolimab injections but do not contain any medicine. Every participant has a 2 in 3 chance of being in the spesolimab group. In the beginning, participants get the study medicine as an injection into a vein. Afterwards, they get it as an injection under the skin every month. After 4 months, participants in the placebo group switch to spesolimab treatment. Participants are in the study for about 1 year. During this time, they visit the study site 16 times. Where possible, 4 of 16 visits can be done at the participant's home instead of the study site. The doctors regularly check participants' NS symptoms. The results are compared between the groups to see whether spesolimab works. The doctors also regularly check participants' general health and take note of any unwanted effects.
Status | Recruiting |
Enrollment | 39 |
Est. completion date | January 3, 2028 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: - Male or female patients, aged 12 years and older (weight minimum is 35kg). - Confirmed diagnosis of Netherton syndrome (NS) (causative SPINK5 mutations) at baseline (Visit 2). - At least moderate severity of erythema at baseline (visit 2) (Ichthyosis Area Severity Index (IASI) score = 16 and IASI-Erythema (E) score =8) and = 3 on Investigator Global Assessment (IGA) score. - Signed and dated written informed consent and assent in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission in the trial - Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the clinical trial protocol (CTP) as well as in the patient, parent(s) (or patient's legal guardian) information. Exclusion Criteria: - Patients who have used topical corticosteroids (medium to high, US class I-V), topical retinoids, topical calcineurin inhibitors or keratolytics within 1 week prior to randomisation - Patients who have used emollient on the area to be biopsied in the previous 24 hours - Patients who have used systemic retinoids, other systemic immunosuppressants, systemic corticosteroids or phototherapy within 4 weeks prior to randomisation - Patients who have used systemic antibiotics within 2 weeks prior to randomisation - Patients who have received live vaccines within 4 weeks prior to randomisation - Patients who have received investigational products, biologics or immunoglobulins within 4 weeks or 5 half-lives (whichever is longer) prior to randomisation - Severe, progressive, or uncontrolled hepatic disease, defined as >3-fold Upper Limit of Normal (ULN) elevation in Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) or alkaline phosphatase, or >2-fold ULN elevation in total bilirubin - Patients who have any prior exposure to BI 655130 or another interleukin 36 receptor (IL-36R) inhibitor biologics - Further exclusion criteria apply |
Country | Name | City | State |
---|---|---|---|
Australia | Westmead Hospital | Westmead | New South Wales |
Belgium | UZ Leuven | Leuven | |
Bulgaria | ASMC-IPSMC-skin and Veneral Diseases | Sofia | |
China | Beijing Children's Hospital, Capital Medical University | Beijing | |
China | Southern Medical University Dermatology Hospital | Guangzhou | |
China | The Children's Hospital Zhejiang University School Of Medicine | Hangzhou | |
China | The First Affiliated Hospital, Zhejiang University | Hangzhou | |
China | Dermatology Hospital, Chinese Academy of Medical Sciences | Nanjing | |
China | Shanghai Skin Disease Hospital | Shanghai | |
China | Xinhua Hospital Affiliated to Shanghai Jiaotong University | Shanghai | |
Finland | Suomen Terveystalo oy Tampere | Tampere | |
France | HOP Saint-Louis | Paris | |
Germany | Universitätsklinikum Erlangen | Erlangen | |
Germany | Universitätsklinikum Heidelberg | Heidelberg | |
Germany | Universitätsklinikum Schleswig-Holstein, Campus Kiel | Kiel | |
Germany | Klinikum der Universität München AÖR | München | |
Israel | Sourasky Medical Center | Tel Aviv | |
Italy | Istituto Dermopatico Dell'Immacolata - IDI - IRCCS | Roma | |
Italy | AO Città della Salute e Scienza | Torino | |
Japan | Nagoya University Hospital | Aichi, Nagoya | |
Japan | Juntendo University Urayasu Hospital | Chiba, Urayasu | |
Japan | Okayama University Hospital | Okayama, Okayama | |
Malaysia | Hospital Tunku Azizah | Kuala Lumpur | |
Malaysia | Sunway Medical Centre | Selangor Darul Ehsan | |
Netherlands | Erasmus MC - Sophia Kinderziekenhuis | Rotterdam | |
Portugal | ULS de São José, E.P.E. - Hospital Sto. António Capuchos | Lisboa | |
Switzerland | University Children Hospital Zürich | Zürich | |
United Kingdom | Queen Elizabeth University Hospital | Glasgow | |
United States | Yale University School of Medicine | New Haven | Connecticut |
United States | Virginia Clinical Research, Inc. | Norfolk | Virginia |
United States | Mission Dermatology Center | Rancho Santa Margarita | California |
Lead Sponsor | Collaborator |
---|---|
Boehringer Ingelheim |
United States, Australia, Belgium, Bulgaria, China, Finland, France, Germany, Israel, Italy, Japan, Malaysia, Netherlands, Portugal, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | IASI response | Ichthyosis Area Severity Index (IASI) response is defined as a decrease of at least 50 % absolute change in IASI score from baseline at Week 16. | At baseline and at Week 16. | |
Secondary | Key secondary endpoint: IGA response | Investigator Global Assessment (IGA) | at Week 16. | |
Secondary | IGA response | Investigator Global Assessment (IGA) | up to Week 12. | |
Secondary | IASI response | Ichthyosis Area Severity Index (IASI) | At baseline and up to Week 12. | |
Secondary | IASI-E subscore response | Ichthyosis Area Severity Index - Erythema (IASI-E) | At baseline and up to Week 16. | |
Secondary | IASI-S subscore response | Ichthyosis Area Severity Index - Scaling (IASI-S) | At baseline and up to Week 16 | |
Secondary | Percent change from baseline in IASI score | Ichthyosis Area Severity Index (IASI) | At baseline and up to Week 16. | |
Secondary | Absolute change from baseline in NRS pain | The Numeric Pain Rating Scale (NRS) | At baseline and up to Week 16. | |
Secondary | Absolute change from baseline in NRS itch | The Numeric Rating Scale (NRS) | At baseline and up to Week 16. | |
Secondary | Absolute change from baseline in DLQI/CDLQI score | Dermatology Life Quality Index (DLQI)/Children Dermatology Life Quality Index (CDLQI) | At baseline and up to Week 16. | |
Secondary | The occurrence of treatment emergent adverse events including serious and/or opportunistic infections | up to 172 weeks. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05979831 -
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT00208026 -
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT05583669 -
A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01428297 -
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
|
Phase 1 | |
Recruiting |
NCT05789056 -
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT05521438 -
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT05388903 -
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06137157 -
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
|
Phase 1 | |
Not yet recruiting |
NCT05902663 -
Natural History of Netherton Syndrome
|
||
Recruiting |
NCT04244006 -
A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT03417856 -
Defining the Skin and Blood Biomarkers of Ichthyosis
|
||
Completed |
NCT02113904 -
Clinical Trial Using Humira in Netherton Syndrome
|
Phase 2 | |
Recruiting |
NCT05211830 -
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT03041038 -
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
|
Phase 2 | |
Recruiting |
NCT02081313 -
Natural History and Biological Study of Netherton Syndrome
|
N/A | |
Recruiting |
NCT01545323 -
Gene Therapy for Netherton Syndrome
|
Phase 1 |